|Over a week ago|
Thirteen new option listings and two option delistings on November 18th » 08:3011/1811/18/20
CBAT, FVAC, SRRK, PAE, NETL, MP, IMVT, HOMZ, FPH, DEEP, MYOK
New option listings for…
New option listings for November 18th include CBAK Energy Technology Inc (CBAT), United States Copper Index Fund (CPER), Roundhill Acquirers Deep Value ETF (DEEP), EMQQ The Emerging Markets Internet and Ecommerce ETF (EMQQ), Five Point Holdings (FPH), Hoya Capital Housing ETF (HOMZ), iShares Bb Rated Corporate Bond ETF (HYBB), Immunovant Inc (IMVT), MP Materials Corp (MP), Netlease Corporate Real Estate ETF (NETL), PAE Incorporated (Class A Stock) (PAE), Scholar Rock Holdings Corporation (SRRK), and Northshore Global Uranium Mining ETF (URNM). Option delistings effective November 18th include Fortress Value Acquisition Corp (Class A Stock) (FVAC) and MyoKardia Inc (MYOK).
Scholar Rock price target raised to $47 from $33 at Wedbush » 08:4811/1011/10/20
Wedbush analyst David…
Wedbush analyst David Nierengarten raised the firm's price target on Scholar Rock to $47 from $33 and keeps an Outperform rating on the shares. The analyst notes that the company reported Q3 earnings and recently reported positive interim data from the Phase 2 TOPAZ study evaluating apitegromab in patients with SMA Types II and III that showed "encouraging" motor function improvements from baseline. Nierengarten believes the early data support apitegromab's benefit, and its potential to improve over time. Topline 12-month data are slated for Q2 2021 and should give a better measure of true benefit.
Scholar Rock reports Q3 EPS (79c), consensus (55c) » 08:0311/0911/09/20
Reports Q3 revenue $3M,…
Reports Q3 revenue $3M, consensus $7.62M.
|Over a month ago|
Scholar Rock 2.949M share Spot Secondary priced at $39.00 » 06:1910/2910/29/20
The deal size was…
The deal size was increased to $200M in common stock from $150M in common stock. JPMorgan, Jefferies and Credit Suisse acted as joint book running managers for the offering.
Scholar Rock price target raised to $52 from $33 at BMO Capital » 08:5310/2810/28/20
BMO Capital analyst Do…
BMO Capital analyst Do Kim raised the firm's price target on Scholar Rock to $52 from $33 and keeps an Outperform rating on the shares. The analyst cites the company's "positive" interim phase 2 data of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy and believes that the 6-month outcomes for all cohorts "comfortably beat motor function and responder rate hurdles". Kim also increases his probability of success for the program to 50% from 33% following yesterday's update.
Fly Intel: After-Hours Movers » 18:1110/2710/27/20
CYH, DENN, SRRK, SUM, BGFV, AKAM, CHRW, TWOU, UVE, ZYXI, TENB, SWI, CB, FSLR, SKY, MSTR, RRR, FEYE, OKE, JNPR, MKSI, FISV, MTDR
Check out this evening's…
Scholar Rock up 20% to $35.90 after offering, proceeds used in advancing trial » 17:5910/2710/27/20
Shares of Scholar Rock…
Shares of Scholar Rock are up 20% at $35.90 after the company announced an equity offering of $150M, stating that it "intends to use the net proceeds from the offering to advance SRK-015 in Spinal Muscular Atrophy, including costs associated with preparing for and executing clinical trials - including a Phase 3 clinical trial - SRK-181 in cancer immunotherapy, development of its preclinical and discovery programs, as well as for working capital and other general corporate purposes.
Scholar Rock files to sell $150M in common stock » 16:1810/2710/27/20
J.P. Morgan Securities…
J.P. Morgan Securities LLC, Jefferies LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. BMO Capital Markets Corp. is acting as lead manager for the offering.
Scholar Rock price target raised to $39 from $35 at Baird » 10:4810/2710/27/20
Baird analyst Madhu Kumar…
Baird analyst Madhu Kumar raised the firm's price target on Scholar Rock to $39 from $35 and keeps an Outperform rating on the shares. The analyst notes that Scholar Rock has announced 6-month interim data from the Phase 2 TOPAZ trial of antipromyostatin mAb SRK-015 in spinal muscular atrophy types 2/3. Overall, he was pleased by the early clinical POC shown in all cohorts of TOPAZ, especially the dose-dependent improvement in motor function observed in cohort 3. Kumar reiterates the stock status as a Fresh Pick.
Scholar Rock announces six-month interim analysis from TOPAZ Phase 2 » 07:1810/2710/27/20
Scholar Rock announced…
Scholar Rock announced positive six-month interim analysis results from the TOPAZ Phase 2 clinical trial. Treatment with SRK-015 led to improvements in Hammersmith scale scores (primary efficacy endpoint) in all three cohorts of patients with Type 2 and Type 3 Spinal Muscular Atrophy . Dose response in the primary efficacy endpoint was observed across all evaluated timepoints in the double-blind, randomized portion of the trial . The high-dose arm of Cohort 3 attained a 5.6 point mean improvement from baseline in the Hammersmith Functional Motor Scale Expanded as compared to the low dose arm, which attained a 2.4 point mean improvement at the six-month interim analysis timepoint. No safety signals were identified from the interim analysis. "These interim results are important because they demonstrate the potential of this muscle-directed approach to improve motor function of individuals with Type 2 and Type 3 SMA," said Thomas Crawford, M.D., Professor of Neurology at the Johns Hopkins University School of Medicine and Lead Investigator of the TOPAZ trial. "In the last few years, we've celebrated the remarkable success in treating SMA with SMN-upregulating approaches that stabilize against neurodegeneration. These findings highlight the potential for a whole new approach to SMA therapy, used in conjunction with the SMN-enhancing therapies, to address the persistent and significant unmet needs of individuals weakened by SMA." "This is an exciting and important step towards establishing SRK-015 as the potential first muscle-directed therapy for patients with SMA, while also providing important validation of our scientific approach of targeting the latent forms of growth factors," said Yung Chyung, M.D., Chief Medical Officer of Scholar Rock. "These interim data support the continuation of the TOPAZ trial and we look forward to engaging with regulatory authorities regarding our registrational trial plans."